{"id":"NCT01541930","sponsor":"Galderma R&D","briefTitle":"An Open, Uncontrolled Study of GK567 in the Deodorization of Malodorous Fungating Neoplastic Tumours","officialTitle":"An Open, Uncontrolled Study Investigating the Safety and Efficacy of GK567 in the Deodorization of Malodorous Infected Cutaneous Fungating Neoplastic Tumours, Over 14 Days of Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2012-03-01","resultsPosted":"2014-02-06","lastUpdate":"2014-02-06"},"enrollment":21,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Malodorous Infected Cutaneous Ulcer"],"interventions":[{"type":"DRUG","name":"GK567","otherNames":["GK567: Metronidazole Gel 0.75%"]}],"arms":[{"label":"GK567","type":"EXPERIMENTAL"}],"summary":"This clinical trial objective is to investigate the safety and efficacy of GK567 to alleviate malodour of foul smelling, anaerobically infected fungating neoplastic tumours, over 14 days of treatment.\n\nThe clinical hypothesis is that the success rate is no worse than 70% in the population of interest, where success for a patient is defined as a smell score of 0 or 1 at Day 14/end of treatment, as assessed by the Study Investigator.","primaryOutcome":{"measure":"The Success Rate","timeFrame":"at Day 14 (end of treatment)","effectByArm":[{"arm":"GK567","deltaMin":95.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":2,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":21},"commonTop":["Skin neoplasm bleeding","Fatigue","Somnolence","Gamma-glutamyltransferase increased","Nasopharyngitis"]}}